Mental Health

Serotonin transporter occupancy explains sertraline withdrawal symptoms and helps distinguish relapse.

Incretin-based therapies were associated with a lower risk of dementia compared with sulfonylureas in older adults with type 2 diabetes, highlighting potential cognitive benefits relevant to long-term diabetes management.

Real-world FAERS data reveal venlafaxine’s known risks plus rare late-onset events and subgroup patterns, guiding long-term prescribing.

Although historically conceptualized as a childhood condition, it is now well established that ADHD frequently continues across the life span, with symptoms evolving rather than resolving.

The HHS secretary overstated preliminary research showing the benefits of a keto diet in patients with schizophrenia who remain adherent to medications.

In addition to increased prevalence, the age of diagnosis has also decreased.

COVID-19 significantly impacts diagnosis rates for depression, asthma, and osteoporosis, revealing health care inequities and the need for improved monitoring.

Discover groundbreaking FDA-approved treatments, including at-home depression therapy, new biosimilars, and culturally relevant pain relief options.

Dextromethorphan offers unique mechanisms and potential benefits over traditional antidepressants.

The study found that anxiety and depression in those with Parkinson disease were significantly associated with fatigue severity.

Recent research links depression to increased risk of Lewy body dementia and Parkinson disease, emphasizing the need for early detection and awareness.

Dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists were found to offer neuroprotective effects to patients who were administered the medications.

The glucagon-like peptide-1 (GLP-1) receptor agonist medications evaluated included semaglutide, tirzepatide, and liraglutide.

The findings reemphasize a need for mental health support for those in the pharmacy profession.

Pharmacists play a vital role in mental health care, enhancing treatment continuity and bridging gaps between mental and physical health for patients with serious mental illness.

To effectively and safely taper benzodiazepines, withdrawal challenges must be addressed while promoting patient involvement.

GLP-1 receptor agonists show potential in reducing alcohol cravings and addiction behaviors, offering hope for treating substance use disorders.

Pharmacists play a vital role in the safe integration of psychedelics into healthcare, addressing ethical concerns and ensuring equitable access to treatments.

Prolonged exposure to specific air pollution components significantly increases depression risk in older adults, highlighting the need for targeted regulations.

Pharmacists must adapt to the evolving landscape of psychedelic therapies, focusing on education, patient support, and understanding regulatory challenges.

Discover the latest FDA-approved treatments, including lumateperone for depression and elinzanetant for menopause symptoms, plus innovative health supplements.

New research explores the gut-brain connection, suggesting that improving gut health may enhance mental well-being.

High levels of C-reactive protein in the blood and lower heart rate variability were linked to cardiovascular events in patients with depression, anxiety, or both.

FDA approves lumateperone as a new adjunct therapy for major depressive disorder, offering hope for those with persistent symptoms despite treatment.

The most impactful FDA approvals of 2025 feature groundbreaking treatments for mental health, STIs, diabetes, pain relief, and cardiovascular health.